KeyBanc Capital Markets initiated coverage of BKV Corp. (NYSE:BKV) with an "overweight" rating and set a price target of $23 ...

Memo Therapeutics has completed patient enrolment for its Phase II trial of potravitug, for BK viremia (BKV) in kidney ...

Fintel reports that on October 21, 2024, Keybanc initiated coverage of BKV (NYSE:BKV) with a Overweight recommendation. What ...

Truist Securities analyst Bertrand Donnes initiated coverage on BKV Corporation (NYSE:BKV) with a Buy rating and a price ...

BKV’s (NYSE:BKV – Get Free Report) quiet period is set to end on Tuesday, November 5th. BKV had issued 15,000,000 shares in its IPO on September 26th. The total size of the offering was $ ...

Analysts at KeyCorp issued their Q3 2024 earnings estimates for shares of BKV in a research note issued to investors on ...

BKV Corporation (NYSE: BKV) (“BKV” or the “Company”) today announced that it will report its third quarter 2024 operational and financial results before markets open on Tuesday ...

KeyBanc initiated coverage of BKV Corp. (BKV) with an Overweight rating and $23 price target BKV is primarily a natural gas-focused ...

2010 - BKV Industries Ltd has appointed Sri. Yadlapalli Srinivasa Rao as Non-executive Independent Director of the Company with effect from April 29, 2010. 2012 - Email ID : investorskaktex@ ...

KeyBanc initiated coverage of BKV Corp. (BKV) with an Overweight rating and $23 price target BKV is primarily a natural gas-focused exploration and production company, the analyst tells investors ...

DENVER, October 30, 2024--(BUSINESS WIRE)--BKV Corporation (NYSE: BKV) ("BKV" or the "Company") today announced that it will report its third quarter 2024 operational and financial results before ...

BKV Corporation (NYSE: BKV) ("BKV" or the "Company") today announced that it will report its third quarter 2024 operational ...